多靶点酪氨酸激酶抑制剂治疗碘难治性甲状腺癌的真实世界疗效与安全性
本研究在德国六家转诊中心回顾性纳入101例局部晚期或转移性碘难治性分化型甲状腺癌患者,接受索拉非尼、仑伐替尼和/或帕唑帕尼治疗。一线治疗中位无进展生存期分别为索拉非尼9个月、仑伐替尼12个月、帕唑帕尼12个月;中位总生存期分别为37、47和34个月。严重并发症发生率仑伐替尼21%、索拉非尼7%、帕唑帕尼13%。
要点
- 索拉非尼、仑伐替尼和帕唑帕尼对多数碘难治性DTC有效。
- 一线仑伐替尼和帕唑帕尼的PFS及6个月生存率似优于索拉非尼。
- 仑伐替尼严重并发症发生率较高,需关注出血、血栓等风险。
核心结论
- 索拉非尼、仑伐替尼和帕唑帕尼是多数碘难治性DTC的有效治疗选择。
- 一线治疗中仑伐替尼和帕唑帕尼的PFS及6个月生存率似优于索拉非尼,但研究回顾性及基线差异限制直接比较。
研究设计与样本
- 回顾性真实世界研究,纳入德国六家转诊中心的101例局部晚期或转移性碘难治性DTC患者。
- 患者接受索拉非尼、仑伐替尼和/或帕唑帕尼治疗,采用Kaplan-Meier法估计PFS和OS。
主要发现
- 一线索拉非尼(n=33)中位PFS为9个月(95%CI 5.2-12.8),仑伐替尼(n=53)为12个月(95%CI 4.4-19.6),帕唑帕尼(n=15)为12个月(95%CI 4.4-19.6)。
- 一线索拉非尼中位OS为37个月(95%CI 10-64),仑伐替尼为47个月(95%CI 15.5-78.5),帕唑帕尼为34个月(95%CI 20.2-47.8)。
- 严重并发症(如出血、急性冠脉综合征、血栓/静脉血栓栓塞)在仑伐替尼组75例中16例(21%)、索拉非尼组42例中3例(7%)、帕唑帕尼组24例中3例(13%)。
临床怎么用
- 索拉非尼、仑伐替尼和帕唑帕尼均可用于碘难治性DTC,选择时需权衡疗效与严重并发症风险。
- 仑伐替尼严重并发症发生率较高,治疗期间应加强出血、血栓和心血管事件监测。
局限性
- 研究为回顾性设计。
- 索拉非尼和帕唑帕尼组在TKI批准前时代启动治疗,疾病分期更晚,限制TKIs间直接比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: The management of patients with locally advanced or metastatic differentiated thyroid cancer (DTC) that is refractory to radioiodine (RAI) remains a therapeutic challenge. The multi-tyrosine kinase inhibitors (TKIs) sorafenib and lenvatinib have been approved based on phase 3 clinical trials. Patients and Methods: We aimed at describing the efficacy and safety of TKI treatment of RAI-refractory DTC in a real-world setting at six German referral centers. One hundred and one patients with locally advanced or metastatic RAI-refractory DTC treated with sorafenib, lenvatinib, and/or pazopanib were included. Progression-free survival (PFS) and overall survival (OS) probabilities were estimated by using the Kaplan-Meier method. Results: Ninety-seven of 101 patients had progressive disease before TKI initiation. The median PFS for first-line treatment with sorafenib (n = 33), lenvatinib (n = 53), and pazopanib (n = 15) was 9 (95% confidence interval 5.2-12.8), 12 (4.4-19.6), and 12 months (4.4-19.6), respectively. The median OS for first-line treatment was 37 (10-64) for sorafenib, 47 (15.5-78.5) for lenvatinib, and 34 months (20.2-47.8) for pazopanib. Serious complications (e.g., hemorrhage, acute coronary syndrome, and thrombosis/venous thromboembolism) occurred in 16 out of 75 (21%) patients taking lenvatinib, in 3 out of 42 (7%) patients taking sorafenib, and in 3 out of 24 (13%) patients taking pazopanib. Conclusions: Sorafenib, lenvatinib, and pazopanib are effective treatment options in the majority of patients with RAI-refractory DTC. The PFS and six-month survival rate in patients treated with lenvatinib und pazopanib appear to compare favorably with sorafenib in the first-line treatment setting. However, a more advanced disease stage at treatment initiation in sorafenib- and pazopanib-treated patients in the era before TKI-approval and the retrospective nature of this study precludes a direct comparison of TKIs.
引用
- Koehler VF, Berg E, Adam P, et al. Real-World Efficacy and Safety of Multi-Tyrosine Kinase Inhibitors in Radioiodine Refractory Thyroid Cancer. Thyroid. 2021. PMID: 34405734. doi:10.1089/thy.2021.0091
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。